A Novel LINC00478/LINC01549 Intergenic Region-ALK Fusion Responded Well to Alectinib in a Patient With Lung Adenocarcinoma
Wei Peng, MS,
Si Li, PhD,
Lijian Li, PhD,
Mingzhe Xiao, PhD,
Jincai Zhong, MD
Affiliations
Wei Peng, MS
Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China
Si Li, PhD
The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co. Ltd., Nanjing, People’s Republic of China
Lijian Li, PhD
The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co. Ltd., Nanjing, People’s Republic of China
Mingzhe Xiao, PhD
The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co. Ltd., Nanjing, People’s Republic of China
Jincai Zhong, MD
Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China; Corresponding author. Address for correspondence: Jincai Zhong, MD, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, People’s Republic of China.
